Voyageur Pharmaceuticals Ltd. is advancing its strategy to establish a vertically integrated supply chain for barium and iodine contrast media drugs, targeting critical vulnerabilities in the diagnostic imaging sector. The global demand for diagnostic imaging pharmaceuticals is projected to grow from US$6.77 billion in 2024 to US$13.86 billion by 2033, according to Research Contrast, highlighting the strategic importance of securing reliable production.
The company's approach involves controlling the entire value chain from mineral discovery to finished product manufacturing. This vertical integration aims to ensure supply security and competitive production costs, particularly significant given that barite is classified as a critical mineral by the U.S. Geological Survey. Voyageur is currently focused on completing two bankable feasibility studies that underpin this strategy: the Voyageur Radiology Iodine & Barium Drug Manufacturing Project and the Bayer Iodine Project.
For its barium strategy, Voyageur is advancing the Frances Creek project, which hosts an indicated and inferred mineral resource of 132,000 tonnes of pharmaceutical grade barium sulfate. Recent testing confirms the barite purity exceeds Pharmaceutical Grade requirements, averaging 98.8% BaSO4. The company has already generated approximately C$32,000 in initial contrast product sales through five Health Canada approved barium products manufactured with Alberta Veterinary Laboratories, establishing commercial validation for its approach.
Voyageur completed a preliminary economic assessment that valued the Frances Creek barium contrast project with a net present value of $344 million, as detailed in a news release dated January 11, 2022. The company is building client networks in Canada while developing international sales opportunities in Latin America, Middle East, North Africa, and Asia-Pacific regions to enhance the ongoing feasibility study and future market penetration.
Regulatory pathways are progressing with Voyageur having formally commenced the FDA approval process in February 2026 via the 505(b)(2) regulatory pathway. The company expects an 18 to 24-month review and approval process, potentially enabling U.S. barium market entry by mid to late 2027. FDA approval, recognized globally, would also facilitate product registration in the European Union and other international markets, significantly expanding Voyageur's growth opportunities.
For iodine contrast media, Voyageur is advancing a prefeasibility study that integrates the Mueller iodine extraction process with the Streamline iodine drug manufacturing platform. The project targets 35 million doses per year of iodine contrast drug production using iodine-rich brine sourced from oil and gas operations in the United States. The combined processes are expected to significantly lower manufacturing costs for iodine drugs.
The Bayer Iodine Project represents another cornerstone of Voyageur's strategy, supported by US$2.35 million in funding. This collaboration, which began with the signing of a letter of intent with Bayer on December 20, 2024, could advance to a second phase involving offtake-linked production financing. In this potential arrangement, Bayer would provide capital financing while Voyageur would operate and manage the project, with all intellectual property remaining exclusively owned by Voyageur.
Voyageur is engaging with a global engineering company to complete the final two feasibility studies. The company is on track to deliver these studies, positioning itself to establish a secure, large-scale North American supply of essential contrast media drugs. Upon completion, Voyageur will have finalized the economics and plant design to vertically produce iodine and barium contrast media drugs, potentially becoming the only vertically integrated radiology drug company in the marketplace.
The company is actively reviewing financial options to fund future capital expenditures, targeting construction to commence in 2027 based on finalized feasibility studies. Every initiative underway aims to position Voyageur as the only vertically integrated manufacturer of barium and iodine contrast media globally, providing affordable and secure supplies for healthcare authorities worldwide through its "From Earth to Bottle" value proposition.
